DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Acanthosis nigricans

Essential points for quick revision.

Synopsis

Recognise the velvety flexural phenotype, investigate common metabolic and endocrine drivers without stigma, and identify the rare sudden extensive pattern that can signal internal malignancy.

  • Acanthosis nigricans is velvety thickened hyperpigmented skin, usually on the posterior neck, axillae or groins; texture and distribution are more diagnostic than colour alone.
  • Insulin resistance associated with higher adiposity, type 2 diabetes or polycystic ovary syndrome is the commonest acquired context, but the sign is not itself a glucose diagnosis.
  • Examine respectfully in good light and ask permission before folds are exposed; in dark skin the change may be prominent, but baseline pigmentation must not be pathologised.

Key red flags

Abrupt rapidly progressive acanthosis in an older adult, especially with weight loss, marked itch, mucosal involvement, tripe palms or no metabolic explanation, requires expedited investigation for an internal malignancy.

Malignant-pattern warning

Rapid widespread itch, mucosal papillomatosis, tripe-like palms and weight loss in an older person demand expedited systemic assessment.

Investigation priorities

01
HbA1c or fasting plasma glucoseFirst step

Detect prediabetes or type 2 diabetes in a metabolically plausible phenotype.

Management branches

Typical metabolic patternMeasure risk without making assumptions

Stable flexural acanthosis occurs with plausible insulin resistance and no malignant warning features.

  1. Confirm velvety thickening by examination, document onset and family tendency, and ask about cycles, hair change, medicines, sleep and symptoms of hyperglycaemia.
  2. Measure blood pressure and arrange HbA1c or fasting glucose plus lipids and other cardiovascular assessment according to age and risk.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom